Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 20/20 | 0.75 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.75 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21418843 | 1.00 | P2RY2 (0.75) | P2RY2P2RY4P2RY6 | |
| SCHEMBL21418842 | 1.00 | P2RY2 (0.75) | P2RY2P2RY4P2RY6 | |
| SCHEMBL17972336 | 1.00 | P2RY2 (0.75) | P2RY2P2RY4P2RY6 | |
| SCHEMBL3502990 | 1.00 | P2RY2 (0.75) | P2RY2P2RY4P2RY6 | |
| SCHEMBL15810740 | 1.00 | P2RY2 (0.75) | P2RY2P2RY4P2RY6 | |
| SCHEMBL24371631 | 0.92 | P2RY2 (0.66) | P2RY2P2RY4P2RY6 | |
| SCHEMBL21418572 | 0.92 | P2RY2 (0.64) | P2RY2P2RY4P2RY6 | |
| SCHEMBL24371531 | 0.92 | P2RY2 (0.66) | P2RY2P2RY4P2RY6 | |
| SCHEMBL24372005 | 0.92 | P2RY2 (0.66) | P2RY2P2RY4P2RY6 | |
| SCHEMBL16575673 | 0.92 | P2RY2 (0.66) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | claimed |
| US-20250136711-A1 | SEMENOGELIN NEUTRALIZING ANTIBODY AND EPITOPE AND APPLICATION THEREOF | SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD (CN) | 2025-05-01 | — | — | US | claimed |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| CN-118924887-A | HPV MRNA LNP vaccine | 南京吉迈生物技术有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | MODERNATX, INC. (US) | 2024-05-14 | — | — | US | claimed |
| US-11951120-B2 | Modification of gene transcription and translation efficiency by 5′UTR sequence variation | Nanjing GeneLeap Biotechnology Co., Ltd. | 2024-04-09 | — | — | US | claimed |
| US-20230310484-A1 | Modification of Gene Transcription and Translation Efficiency by 5'UTR Sequence Variation | Nanjing GeneLeap Biotechnology Co., Ltd. (CN) | 2023-10-05 | — | — | US | claimed |
| CN-116179549-A | Modification of gene transcription and translation efficiency by 5' UTR sequence variants | 南京吉迈生物技术有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | MODERNATX, INC. (US) | 2023-02-16 | — | — | US | claimed |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2083851-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | Curevac GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-2008052770-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
| US-20030039976-A1 | Methods for base counting | PE CORPORATION (NY) | 2003-02-27 | — | — | US | claimed |
| EP-1261339-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | Pharmacia Corporation (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001060366-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS | PHARMACIA CORPORATION (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1007058-A1 | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. Searle & Co. (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1998035685-A1 | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | G.D. SEARLE AND CO. (US) | 1998-08-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | RNGTT, UPF1, RNMT | P2RY2 4412/4885P2RY4 4672/4885P2RY6 4640/4885 |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | P2RY2 2992/4885P2RY4 2730/4885P2RY6 2967/4885 |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | RNMT, RNASE1, NSUN3 | P2RY2 4516/4885P2RY4 4740/4885P2RY6 4642/4885 |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | RNGTT, UPF1, RNMT | P2RY2 4412/4885P2RY4 4672/4885P2RY6 4640/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885P2RY6 3298/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY4 4107/4885P2RY6 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.